[Nedaplatin combined with tegafur in the treatment for advanced esophageal cancer].
OBJECTIVE
To investigate the efficacy and toxicity of nedaplatin combined with tegafur in the treatment for patients with advanced esophageal cancer.


METHODS
Among the 65 patients with advanced esophageal cancer, 27 had no history of prior chemotherapy and the other 38 had ever received postoperative adjuvant chemotherapy before. The median age of those cases was 58.0 years. Nedaplatin was given daily by intravenous infusion at a dose of 20 mg/m(2) for 2 hours and tegafur at a dose of 500 mg/m(2) for 8 hours on D1 approximately D5, every 21 days as a cycle.


RESULTS
193 cycles of chemotherapy were accomplished in the 65 patients, and 63 patients were evaluable for response evaluation. Of 27 patients with no prior history of chemotherapy, 6 achieved complete response and 16 partial response, with a response rate (CR + PR) of 81.5%. Among the 36 patients who had ever received postoperative adjuvant chemotherapy, 6 obtained complete response and 10 partial response with a response rate (CR + PR) of 44.4%. The overall median time to tumor progression in this series was 5.6 months. The overall median actuarial survival was 9.3 months, and the one-year survival rate was 24.9%. Nausea and vomiting were the major toxicities, but were mild and well tolerable. Grade 3 to 4 neutropenia was only observed in two patients (3.2%).


CONCLUSIONS
The regimen of nedaplatin combined with tegafur is effective and tolerable for the treatment of advanced esophageal cancer.
Fan
Qing-Xia
QX
Depratment of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou 450052, China.
Wang
Rui
R
Lu
Ping
P
Zhao
Yong-Fu
YF
Lu
Tai-Ying
TY
Han
Jian-Wei
JW
Wang
Jun-Sheng
JS
Luo
Su-Xia
SX
Lu
Shou-Ping
SP
Wang
Gui-Ji
GJ
Geng
Li
L
Zhang
Ming-Zhi
MZ
Ma
Zhi-Yong
ZY
Song
Min
M
Wu
Xin-Ai
XA
Chen
Xiao-Bing
XB
Jiao
Zhi-Min
ZM
Wang
Rui-Lin
RL
D000230:Adenocarcinoma / Q000188:drug therapy / Q000473:pathology; D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy* / Q000473:pathology; D004938:Esophageal Neoplasms / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D009325:Nausea / Q000139:chemically induced; D009367:Neoplasm Staging; D009503:Neutropenia / Q000139:chemically induced; D009944:Organoplatinum Compounds / Q000008:administration & dosage / Q000009:adverse effects; D012074:Remission Induction; D015996:Survival Rate; D005641:Tegafur / Q000008:administration & dosage / Q000009:adverse effects; D014839:Vomiting / Q000139:chemically induced
D009944:Organoplatinum Compounds; D005641:Tegafur; C053989:nedaplatin